Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) CEO Jay R. Luly sold 27,912 shares of the firm’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $45.16, for a total transaction of $1,260,505.92. Following the transaction, the chief executive officer now directly owns 819,810 shares in the company, valued at approximately $37,022,619.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Enanta Pharmaceuticals Stock Up 0.2 %
ENTA stock opened at $45.17 on Wednesday. The firm has a 50 day moving average of $49.73 and a 200 day moving average of $49.18. The stock has a market capitalization of $943.60 million, a PE ratio of -7.76 and a beta of 0.40. Enanta Pharmaceuticals, Inc. has a 52 week low of $37.59 and a 52 week high of $79.50.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last released its earnings results on Tuesday, February 7th. The biotechnology company reported ($1.39) EPS for the quarter, topping analysts’ consensus estimates of ($1.52) by $0.13. The company had revenue of $23.60 million during the quarter, compared to analysts’ expectations of $22.48 million. Enanta Pharmaceuticals had a negative net margin of 146.93% and a negative return on equity of 36.59%. Enanta Pharmaceuticals’s revenue for the quarter was down 14.5% on a year-over-year basis. During the same period last year, the business earned ($1.48) EPS. On average, equities research analysts expect that Enanta Pharmaceuticals, Inc. will post -7.36 earnings per share for the current year.
Institutional Trading of Enanta Pharmaceuticals
Wall Street Analyst Weigh In
A number of research analysts have commented on ENTA shares. Oppenheimer set a $50.00 target price on shares of Enanta Pharmaceuticals in a research report on Thursday, November 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $87.00 price objective on shares of Enanta Pharmaceuticals in a research report on Wednesday, February 8th. JMP Securities reaffirmed a “buy” rating and issued a $96.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 22nd. JPMorgan Chase & Co. cut their price objective on shares of Enanta Pharmaceuticals from $74.00 to $60.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 8th. Finally, Royal Bank of Canada cut their price objective on shares of Enanta Pharmaceuticals from $65.00 to $54.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 22nd. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $68.60.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.
- Get a free copy of the StockNews.com research report on Enanta Pharmaceuticals (ENTA)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.